No Data
Is it the most 'rolled up' in history? The tenth batch of national procurement pharmaceutical catalog is officially announced, with up to 31 companies competing for a single variety.
①This afternoon, the National Pharmaceutical Centralized Procurement Office officially announced the tenth batch of national procurement pharmaceutical catalog, with a total of 263 specifications and 62 varieties; ②Many industry insiders believe that the tenth batch of national procurement will be the largest and most competitive national procurement in history.
Express News | 建银国际: Downgraded cspc pharma to Neutral, with a target price of 5.70 Hong Kong dollars.
Dah Sing: Sino Biopharmaceutical (01093.HK) performance in the third quarter is far below expectations, expecting the market to adjust forecasts for this year and beyond.
Morgan Stanley released a report stating that Sihuan Pharmaceutical (01093.HK) preliminary profit for the third quarter plummeted by 50.6% year-on-year to 0.755 billion RMB, far below expectations. The management attributes the profit decline to finished drug sales falling far below expectations, with a decrease of 19%, much worse than the bank's expected 3% decline. It is expected that the market will lower Sihuan Pharmaceutical's forecasts for this year and beyond. Morgan Stanley maintains a "shareholding" rating for Sihuan Pharmaceutical with a target price of 6.9 yuan. The report mentioned that tumor drug sales in the previous quarter for Sihuan Pharmaceutical declined by 31% year-on-year, even worse than Morgan Stanley's expected 20% decline, due to drugs like Duomeisu facing challenges from the central authorities.
Hong Kong stock market news | Issuing profit warning, cspc pharma opens 13% lower.
November 1st, gloonhui | cspc pharma (1093.HK) opened 13.04% lower at 5 Hong Kong dollars, hitting a new low since September 24th. The company issued a profit warning last night, estimating that the profit attributable to owners of the company for the nine months ending September 30, 2024, will decrease by approximately 16% from the company's profit attributable to owners of approximately RMB 4,494,641,000 for the same period last year. (Glonhui)
Selected Announcement | li auto inc Q3 revenue increased by 23.6% year-on-year to 42.874 billion yuan; cspc pharma's net profit in the first 9 months decreased by 16% year-on-year to 4.495 billion yuan
Huishang Bank's revenue in the first 9 months was 29.655 billion yuan, a year-on-year increase of 2.66%; Asia Cement's revenue in the first 9 months was 4.119 billion yuan, a year-on-year decrease of 27.94%, resulting in a loss of 0.459 billion yuan.
cspc pharma (01093.HK) issued a profit warning: expected profit for the first three quarters to decrease by about 16%.
CSPC Pharma (01093.HK) announced on October 29th that the company expects the attributable net profit of the company's owners for the nine months ending on September 30, 2024 to decrease by approximately 16% compared to the same period last year, to about RMB 4,494,641,000. The decrease in profit is mainly due to a decrease in revenue from pharmaceutical business by about 3% compared to the same period last year. The main reasons are as follows: (i) In the field of anti-tumor treatment, the prices of two products, Jingyouli and Domeisuo, in the Jing-Jin-Ji '3+N' alliance centralized procurement were reduced by about 58% and 23% respectively, as the alliance procurement took place in March of this year.
No Data
No Data